Retrophin completes acquisition of Orphan Technologies and with it OT 58 for the treatment of classical homocystinuria

Retrophin, Inc. announced the completion of its previously announced acquisition of Orphan Technologies Limited, a privately held, clinical-stage biopharmaceutical company focused on the development of product candidate OT 58 for the treatment of classical homocystinuria (HCU). OT 58 is a novel investigational human enzyme replacement therapy being evaluated in Phase 1/II development for the treatment of classical HCU, a rare metabolic disorder characterized by elevated levels of plasma homocysteine that can lead to life-threatening thrombotic events such as stroke and heart attacks, ophthalmologic and skeletal complications, as well as developmental delay.